What is Zacks Research’s Estimate for COCP FY2028 Earnings?

Cocrystal Pharma, Inc. (NASDAQ:COCP) – Zacks Research issued their FY2028 earnings per share (EPS) estimates for shares of Cocrystal Pharma in a research note issued to investors on Tuesday, April 7th. Zacks Research analyst D. Bautz forecasts that the company will post earnings per share of ($0.70) for the year. The consensus estimate for Cocrystal Pharma’s current full-year earnings is ($1.85) per share.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Cocrystal Pharma in a report on Monday, December 22nd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $6.00.

Cocrystal Pharma Trading Down 2.0%

Shares of NASDAQ:COCP opened at $1.44 on Wednesday. Cocrystal Pharma has a 1-year low of $0.86 and a 1-year high of $2.67. The firm has a market capitalization of $19.86 million, a PE ratio of -1.82 and a beta of 1.18. The business’s 50 day moving average is $1.06 and its 200-day moving average is $1.07.

Cocrystal Pharma (NASDAQ:COCP) last announced its quarterly earnings data on Tuesday, March 31st. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.01.

Insider Activity at Cocrystal Pharma

In related news, Director Phillip Md Et Al Frost bought 50,000 shares of the business’s stock in a transaction that occurred on Friday, February 6th. The stock was acquired at an average price of $0.95 per share, for a total transaction of $47,500.00. Following the transaction, the director directly owned 1,888,551 shares of the company’s stock, valued at $1,794,123.45. This represents a 2.72% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 28.14% of the stock is owned by company insiders.

Hedge Funds Weigh In On Cocrystal Pharma

A hedge fund recently bought a new stake in Cocrystal Pharma stock. DRW Securities LLC bought a new position in shares of Cocrystal Pharma, Inc. (NASDAQ:COCP) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 33,593 shares of the company’s stock, valued at approximately $33,000. DRW Securities LLC owned 0.24% of Cocrystal Pharma at the end of the most recent reporting period. Hedge funds and other institutional investors own 6.72% of the company’s stock.

About Cocrystal Pharma

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.